Cohort Studyhigh evidence
Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.
Lancet (London, England)·October 31, 2026·PMID 42956772
Why it mattersWith approved MASLD therapies emerging, reliable non-invasive tests are needed to identify patients with at-risk MASH and advanced fibrosis for treatment and trial enrollment. This study provides head-to-head performance data across many biomarkers, informing selection of testing strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled